Approval · Notice of Compliance 36220 · 2025
BAT: Notice of Compliance 36220
Issued October 16, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36220
- Date
- October 16, 2025
- Company
- Emergent Biosolutions Canada IncWinnipeg, Manitoba, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in drug substance manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BAT | Not yet assigned | — |
Medicinal ingredients
- BOTULINUM ANTITOXIN SEROTYPE A 4,500 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE B 3,300 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE C 3,000 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE D 600 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE E 5,100 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE F 3,000 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE G 600 UNIT per VIAL